How to treat lung inflammation in a rat? - briefly
Intraperitoneal injection of a corticosteroid (e.g., dexamethasone 0.5 mg/kg) together with a bronchodilator such as albuterol reduces pulmonary inflammation, and supportive care includes humidified oxygen and analgesia. Anti‑inflammatory antibiotics (e.g., enrofloxacin) can be added to treat secondary infection when necessary.
How to treat lung inflammation in a rat? - in detail
Lung inflammation in rodents can be managed through a systematic approach that includes induction verification, therapeutic selection, dosage calculation, administration method, and outcome monitoring.
Verification of the inflammatory state relies on clinical observation (elevated respiratory rate, labored breathing), imaging (micro‑CT or radiography), and biochemical markers (increased cytokines such as IL‑1β, TNF‑α in bronchoalveolar lavage fluid). Histopathology confirms cellular infiltrates and edema.
Therapeutic options fall into three categories: anti‑inflammatory agents, immunomodulators, and supportive measures.
-
Anti‑inflammatory agents
– Non‑steroidal anti‑inflammatory drugs (NSAIDs) such as meloxicam, administered orally at 1–2 mg kg⁻¹ once daily.
– Corticosteroids (e.g., dexamethasone) injected intraperitoneally at 0.5 mg kg⁻¹, repeated every 24 h for up to three days. -
Immunomodulators
– Cytokine‑targeted antibodies (anti‑TNF‑α, anti‑IL‑6) given intravenously at 5 mg kg⁻¹, with dosing intervals determined by pharmacokinetic data.
– Small‑molecule inhibitors of NF‑κB pathway (e.g., BAY 11‑7082) delivered intratracheally at 0.2 mg kg⁻¹, once daily. -
Supportive measures
– Supplemental oxygen provided via a sealed chamber at 30 % FiO₂.
– Hydration maintained with subcutaneous isotonic saline (10 mL kg⁻¹) every 12 h.
– Analgesia ensured by buprenorphine (0.05 mg kg⁻¹, subcutaneously) to reduce stress‑induced exacerbation.
Dosing calculations must consider the animal’s weight, route‑specific bioavailability, and species‑specific metabolism. For oral agents, use a vehicle such as 0.5 % methylcellulose; for injectable compounds, employ sterile saline or appropriate buffer.
Monitoring includes daily measurement of body weight, temperature, and respiratory parameters. Blood samples collected on days 1, 3, and 7 post‑treatment allow quantification of inflammatory markers using ELISA kits. End‑point assessment comprises histological scoring of lung sections stained with hematoxylin‑eosin.
Adjustment of therapy follows observed response: lack of improvement after 48 h warrants escalation to combined corticosteroid‑immunomodulator regimens; excessive immunosuppression indicated by secondary infection requires antibiotic coverage (e.g., enrofloxacin 10 mg kg⁻¹, subcutaneously, once daily).
All procedures must comply with institutional animal care guidelines, employing aseptic technique, proper anesthesia (isoflurane 2–3 % in oxygen), and humane endpoints.